Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
NEW YORK, Feb. 27, 2018 -- Eyenovia Inc. (“Eyenovia”) (NASDAQ:EYEN), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to deliver micro-therapeutics topically to the eye, today announced that Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer is scheduled to present at the 30th Annual ROTH Conference taking place on March 11-13, 2018 at The Ritz-Carlton in Dana Point, California.
Details of the presentation are below:
Event: 30th Annual ROTH Conference
Date: Monday, March 12, 2018
Time: 12:30pm PT / 3:30pm ET
A live webcast of the presentation may be accessed at http://wsw.com/webcast/roth32/eyen/ or on the Company's website at http://eyenoviabio.com. The webcast will be archived for 90 days following the live presentation on the Company's website.
About Eyenovia
Eyenovia is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for micro-therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of micro-therapeutics for glaucoma and other eye diseases.
Company Contact:
Eyenovia Inc.
John Gandolfo
Chief Financial Officer
[email protected]
Investor Contact:
Lee Roth / Tram Bui
The Ruth Group
Phone: 646-536-7012/7035
E-mail: [email protected]/[email protected]
Media Contact:
The Ruth Group
Kirsten Thomas
508-280-6592
[email protected]
